US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CoLucid Pharmaceuticals

46.53

0.0000

Volume:- -

Turnover:- -

Market Cap:897.20M

PE:-13.52

High:46.53

Open:46.53

Low:46.53

Close:46.53

52wk High:46.65

52wk Low:5.26

Shares:19.28M

Float Shares:4.79M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.4400

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Company Profile

Company Name:

CoLucid Pharmaceuticals

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.colucid.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

CoLucid Pharmaceuticals, Inc., a biopharmaceutical company, develops small molecules for the acute treatment of migraine. Its lead product candidate is Lasmiditan, an oral tablet that is in Phase III clinical program for the acute treatment of migraine headaches in adults. The company is also developing IV lasmiditan, which is in Phase II clinical trial for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings. CoLucid Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Cambridge, Massachusetts.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CLCD/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"CLCD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLCD\",,,,,undefined,":{"symbol":"CLCD","market":"US","secType":"STK","nameCN":"CoLucid Pharmaceuticals","latestPrice":46.525,"timestamp":1488315600000,"preClose":46.525,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":4790000,"shares":19284290,"eps":-3.44,"marketStatus":"Trading","change":0,"latestTime":"02-10 12:44:08 EST","open":46.525,"high":46.525,"low":46.525,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.44,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770757200000},"marketStatusCode":2,"adr":0,"listingDate":1430884800000,"exchange":"NASDAQ","adjPreClose":46.525,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLCD\",,,,,undefined,":{"symbol":"CLCD","floatShares":4790000,"roa":"--","roe":"--","lyrEps":0,"shares":19284290,"dividePrice":0,"high":46.525,"amplitude":0,"preClose":46.525,"low":46.525,"week52Low":5.2558,"pbRate":"--","week52High":46.65,"institutionHeld":0,"latestPrice":46.525,"eps":-3.44,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.44,"open":46.525,"prevYearClose":46.525},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CLCD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2016-08-10","symbol":"CLCD","fiscalQuarterEnding":null,"expectedEps":-0.83,"name":null,"time":"","type":"earning","dateTimestamp":1470801600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2016-05-11","symbol":"CLCD","fiscalQuarterEnding":null,"expectedEps":-0.73,"name":null,"time":"","type":"earning","dateTimestamp":1462939200000,"reportTimeType":"","actualEps":-0.85},{"market":"US","date":"2016-03-02","symbol":"CLCD","fiscalQuarterEnding":null,"expectedEps":-0.66,"name":null,"time":"","type":"earning","dateTimestamp":1456894800000,"reportTimeType":"","actualEps":-0.74},{"market":"US","date":"2015-11-10","symbol":"CLCD","fiscalQuarterEnding":null,"expectedEps":-0.71,"name":null,"time":"","type":"earning","dateTimestamp":1447131600000,"reportTimeType":"","actualEps":-0.59},{"market":"US","date":"2015-08-12","symbol":"CLCD","fiscalQuarterEnding":null,"expectedEps":-0.4,"name":null,"time":"","type":"earning","dateTimestamp":1439352000000,"reportTimeType":"","actualEps":-1.17}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CLCD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CLCD\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.colucid.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0021},{"period":"1month","weight":-0.0002},{"period":"3month","weight":0.016},{"period":"6month","weight":0.0761},{"period":"1year","weight":0.1551},{"period":"ytd","weight":0.0176}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CoLucid Pharmaceuticals, Inc., a biopharmaceutical company, develops small molecules for the acute treatment of migraine. Its lead product candidate is Lasmiditan, an oral tablet that is in Phase III clinical program for the acute treatment of migraine headaches in adults. The company is also developing IV lasmiditan, which is in Phase II clinical trial for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings. CoLucid Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Cambridge, Massachusetts.","exchange":"NASDAQ","name":"CoLucid Pharmaceuticals","nameEN":"CoLucid Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"CLCD\",market:\"US\",,,undefined,":null}}